PubRank

S J Green

Author PubWeight™ 82.03‹?›

Top papers

Rank Title Journal Year PubWeight™‹?›
1 Requirement for transcription factor IRF-1 in NO synthase induction in macrophages. Science 1994 4.50
2 Field trials of the Baby Check score card: mothers scoring their babies at home. Arch Dis Child 1991 4.31
3 Activation of macrophages for destruction of Francisella tularensis: identification of cytokines, effector cells, and effector molecules. Infect Immun 1992 3.09
4 Field trials of the Baby Check score card in hospital. Arch Dis Child 1991 2.64
5 Diversity of sulfate-reducing bacteria in oxic and anoxic regions of a microbial mat characterized by comparative analysis of dissimilatory sulfite reductase genes. Appl Environ Microbiol 1999 2.55
6 Field trials of the Baby Check score card in general practice. Arch Dis Child 1991 2.39
7 Induction of nitric oxide synthase protects against malaria in mice exposed to irradiated Plasmodium berghei infected mosquitoes: involvement of interferon gamma and CD8+ T cells. J Exp Med 1994 1.83
8 Unexpected population distribution in a microbial mat community: sulfate-reducing bacteria localized to the highly oxic chemocline in contrast to a eukaryotic preference for anoxia. Appl Environ Microbiol 1999 1.75
9 Life and death of an intracellular pathogen: Francisella tularensis and the macrophage. Immunol Ser 1994 1.73
10 IFN-gamma inhibits development of Plasmodium berghei exoerythrocytic stages in hepatocytes by an L-arginine-dependent effector mechanism. J Immunol 1991 1.73
11 Differential susceptibility of activated macrophage cytotoxic effector reactions to the suppressive effects of transforming growth factor-beta 1. J Immunol 1991 1.71
12 Randomized clinical trial of diethylstilbestrol versus tamoxifen in postmenopausal women with advanced breast cancer. N Engl J Med 1981 1.70
13 Recognition of E-cadherin on epithelial cells by the mucosal T cell integrin alpha M290 beta 7 (alpha E beta 7). Eur J Immunol 1995 1.47
14 Policies for study monitoring and interim reporting of results. J Clin Oncol 1987 1.41
15 The significance of anti-S sensitization in pregnancy. Clin Lab Haematol 1990 1.30
16 2-Methoxyestradiol: an endogenous antiangiogenic and antiproliferative drug candidate. Cancer Metastasis Rev 2000 1.28
17 The hyaluronate receptor is identical to a glycoprotein of Mr 85,000 (gp85) as shown by a monoclonal antibody that interferes with binding activity. J Biol Chem 1987 1.24
18 Biogeochemical cycling and microbial diversity in the thrombolitic microbialites of Highborne Cay, Bahamas. Geobiology 2010 1.15
19 Randomized trial of bilateral oophorectomy versus tamoxifen in premenopausal women with metastatic breast cancer. J Clin Oncol 1986 1.15
20 Analysis of patient age as an independent prognostic factor for survival in a phase III study of cisplatin-cyclophosphamide versus carboplatin-cyclophosphamide in stages III (suboptimal) and IV ovarian cancer. A Southwest Oncology Group study. Cancer 1993 1.14
21 Co-localization of inducible-nitric oxide synthase and Plasmodium berghei in hepatocytes from rats immunized with irradiated sporozoites. J Immunol 1995 1.12
22 Tissue factor pathway inhibitor inhibits endothelial cell proliferation via association with the very low density lipoprotein receptor. J Biol Chem 2001 1.07
23 Studies on transcriptional regulation of the mucosal T-cell integrin alphaEbeta7 (CD103). Immunology 2001 1.06
24 Identification of a binding site for integrin alphaEbeta7 in the N-terminal domain of E-cadherin. J Biol Chem 1996 1.05
25 Considerations for monitoring and evaluating treatment effects in clinical trials. Control Clin Trials 1984 1.05
26 Adjuvant effects of liposomes containing lipid A: enhancement of liposomal antigen presentation and recruitment of macrophages. Infect Immun 1992 1.01
27 Indolequinone antitumor agents: correlation between quinone structure, rate of metabolism by recombinant human NAD(P)H:quinone oxidoreductase, and in vitro cytotoxicity. J Med Chem 1998 1.00
28 Randomized trial of tamoxifen alone or combined with aminoglutethimide and hydrocortisone in women with metastatic breast cancer. J Clin Oncol 1986 0.97
29 Phase II study of high-dose tamoxifen (NSC-180973) in patients with disseminated malignant melanoma. Cancer 1982 0.96
30 Phase II study of tamoxifen in patients with disseminated malignant melanoma. Cancer Treat Rep 1980 0.96
31 Metastatin: a hyaluronan-binding complex from cartilage that inhibits tumor growth. Cancer Res 2001 0.96
32 Tumor necrosis factor-alpha: central regulatory cytokine in the induction of macrophage antimicrobial activities. Pathobiology 1991 0.95
33 Cytokines that regulate macrophage production of nitrogen oxides and expression of antileishmanial activities. Res Immunol 1991 0.95
34 Generation of nitric oxide and clearance of interferon-gamma after BCG infection are impaired in mice that lack the interferon-gamma receptor. J Inflamm 1997 0.94
35 Performing serial testing of treatment effects. Experientia Suppl 1982 0.90
36 Phase II study of high-dose megestrol acetate in patients with advanced malignant melanoma. Cancer Treat Rep 1982 0.88
37 Megestrol acetate and aminoglutethimide/hydrocortisone in sequence or in combination as second-line endocrine therapy of estrogen receptor-positive metastatic breast cancer: a Southwest Oncology Group phase III trial. J Clin Oncol 1997 0.87
38 A controlled pilot study of high-dose methotrexate as postsurgical adjuvant treatment for primary osteosarcoma. J Clin Oncol 1984 0.86
39 Phase II study of recombinant leukocyte A interferon (IFN-rA) plus cimetidine in disseminated malignant melanoma. J Clin Oncol 1985 0.85
40 Dose-response effects of 2-methoxyestradiol on estrogen target tissues in the ovariectomized rat. Endocrinology 2003 0.84
41 A phase III clinical trial comparing the combination cyclophosphamide, adriamycin, cisplatin with cyclophosphamide, 5-fluorouracil, prednisone in patients with advanced breast cancer. J Clin Oncol 1984 0.82
42 Identification of small molecule binding sites within proteins using phage display technology. Comb Chem High Throughput Screen 2001 0.82
43 Phase II study of recombinant leukocyte A interferon (rIFN-alpha A) in disseminated malignant melanoma. Cancer 1984 0.81
44 Phase II study of the combination of vinblastine, bleomycin, and cisplatin in advanced malignant melanoma. Cancer Treat Rep 1982 0.81
45 Progress report on two clinical trials in women with advanced breast cancer. Trial I: tamoxifen versus tamoxifen plus aminoglutethimide. Trial II: aminoglutethimide in patients with prior tamoxifen exposure. Cancer Res 1982 0.81
46 Could the GI tract be a better portal for antibody therapy? Gut 2006 0.81
47 Phase II study of a combination of mitomycin, doxorubicin and cisplatin in advanced sarcomas. Cancer Chemother Pharmacol 1985 0.81
48 VP-16 + adriamycin vs. adriamycin alone in advanced adenocarcinoma of the breast, phase II, a randomized trial: a Southwest Oncology Group Study. Med Pediatr Oncol 1988 0.80
49 Interaction of anti-cholesterol antibodies with human lipoproteins. J Immunol 1996 0.80
50 Expanded phase II trial of paclitaxel in metastatic breast cancer: a Southwest Oncology Group study. Breast Cancer Res Treat 1998 0.80
51 Macrophage activation: a riddle of immunological resistance. Immunol Ser 1994 0.80
52 Role of atheroma liposomes and malondialdehyde-modified low-density lipoproteins in complement activation. Pathobiology 1996 0.80
53 Inhibition of nitric oxide interrupts the accumulation of CD8+ T cells surrounding Plasmodium berghei-infected hepatocytes. Infect Immun 1997 0.80
54 Alpha-galactosyl-mediated activation of porcine endothelial cells: studies on CD31 and VE-cadherin in adhesion and signaling. Transplantation 1999 0.79
55 Randomized clinical trial of megestrol acetate versus tamoxifen in paramenopausal or castrated women with advanced breast cancer. Am J Clin Oncol 1982 0.79
56 Androgens influence sexual differentiation of embryonic mouse hypothalamic aromatase neurons in vitro. Endocrinology 1994 0.78
57 Analysis of anticholesterol antibodies using hydrophobic membranes. J Immunol Methods 1995 0.78
58 Phase II evaluation of L-alanosine (NSC-153353) for patients with disseminated malignant melanoma. Am J Clin Oncol 1984 0.77
59 Methotrexate as adjuvant treatment for primary osteosarcoma. N Engl J Med 1980 0.77
60 Phase II study of L-alanosine (NSC 153353) in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs 1991 0.77
61 Aromatase-immunoreactivity is localised specifically in neurones in the developing mouse hypothalamus and cortex. Brain Res 1994 0.77
62 Effects on overviews of early stopping rules for clinical trials. Stat Med 1987 0.76
63 Subjective concomitants of motion sickness: quantifying rotation-induced illness in squirrel monkeys. Otolaryngol Head Neck Surg 1987 0.76
64 Phase II study of low-dose recombinant leukocyte A interferon in disseminated malignant melanoma. J Clin Oncol 1984 0.76
65 Clinical development of TLR agonists as adjuvants: "post-alum adjuvant" candidates may reach beyond their intended purpose. Clin Pharmacol Ther 2008 0.76
66 Phase II study: the combination DTIC, BCNU, actinomycin D, and vincristine in disseminated malignant melanoma. Med Pediatr Oncol 1986 0.76
67 Nonrandomized comparison between stent deployment and percutaneous transluminal coronary angioplasty in acute myocardial infarction. Am Heart J 2000 0.75
68 Alcoholic liver disease. Lancet 1995 0.75
69 Phase II study of maytansine in advanced breast cancer. Cancer Treat Rep 1981 0.75
70 A good estrogen. Science 1998 0.75
71 Randomized clinical trial of cyclophosphamide, 5-FU, and prednisone with or without tamoxifen in postmenopausal women with advanced breast cancer. Cancer Treat Rep 1985 0.75
72 Molecular and lipid biomarker analysis of a gypsum-hosted endoevaporitic microbial community. Geobiology 2014 0.75
73 Evaluation of vinblastine administered by 5-day continuous infusion in women with advanced breast cancer. Cancer Treat Rep 1984 0.75
74 Field trials of Baby Check: a scoring system to quantify illness in babies under 6 months. Med Inform (Lond) 1990 0.75
75 Phase II study of chlorozotocin in advanced breast cancer. Cancer Treat Rep 1981 0.75
76 Phase II evaluation of PALA and AMSA for patients with disseminated malignant melanoma. Cancer Treat Rep 1981 0.75
77 Phase II evaluation of mitoxantrone plus cis-platinum in patients with advanced breast cancer. A Southwest Oncology Group study. Invest New Drugs 1994 0.75
78 Phase II study of an aziridinylbenzoquinone (AZQ) in disseminated malignant melanoma. Cancer Treat Rep 1982 0.75
79 Interleukin-2 and the regulation of activated macrophage cytotoxic activities. Adv Exp Med Biol 1992 0.75
80 Failure of bleomycin to improve the therapeutic effects of a combination of cyclophosphamide, doxorubicin, and cisplatin (CAP) in advanced sarcomas. Med Pediatr Oncol 1984 0.75
81 Treatment of recurrent and metastatic carcinoma of the cervix: comparison of doxorubicin with a combination of vincristine and 5-fluorouracil. Gynecol Oncol 1981 0.75
82 Effects of head and body restraint on experimental motion-induced sickness in squirrel monkeys. Aviat Space Environ Med 1985 0.75
83 Synthesis and enantiomeric separation of 2-phthalimidino-glutaric acid analogues: potent inhibitors of tumor metastasis. J Med Chem 1999 0.75
84 Phase II evaluation of bisantrene hydrochloride in refractory malignant melanoma. A Southwest Oncology Group Study. Invest New Drugs 1987 0.75
85 An evaluation of early or delayed adjuvant chemotherapy in premenopausal patients with advances breast cancer undergoing oophorectomy: a later analysis. Am J Clin Oncol 1982 0.75
86 Hemoglobin A1 in renal transplant recipients. Arch Intern Med 1985 0.75
87 Randomized clinical trial of doxorubicin alone or combined with mitolactol in women with advanced breast cancer and prior chemotherapy exposure. Am J Clin Oncol 1985 0.75
88 Phase II study of mitolactol and semustine combination chemotherapy for advanced malignant melanoma. Cancer Treat Rep 1982 0.75
89 Saralasin acetate test in renal transplant hypertension. Report of 17 cases and a review of the literature. Arch Intern Med 1984 0.75
90 Relation of angina pectoris to coronary artery disease in aortic valve stenosis. Am J Cardiol 1985 0.75
91 Frequency of angiographically significant coronary arterial narrowing in mitral stenosis. Am J Cardiol 1986 0.75
92 Non-renin dependent hypertension in renal allograft rejections. A structural and functional analysis. Arch Pathol Lab Med 1984 0.75
93 The role of early radionuclide ejection fraction in predicting early mortality after acute myocardial infarction in the elderly. Mt Sinai J Med 1985 0.75
94 Evaluation of mitolactol in women with advanced breast cancer and prior chemotherapy exposure. Cancer Treat Rep 1983 0.75